ARTICLE | Clinical News

Trailblaze Pharos regulatory update

November 18, 2016 6:28 PM UTC

Ignyta said it received CE Mark approval for its Trailblaze Pharos companion diagnostic to identify patients who have solid tumors with neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1), TrkB, TrkC, c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) or anaplastic lymphoma kinase (ALK) gene rearrangements leading to fusion proteins. Trailblaze Pharos is the proposed companion diagnostic for Ignyta’s entrectinib (formerly RXDX-101), which is in Phase II testing to treat patients with solid tumors harboring TrkA, TrkB, TrkC, ROS1 or ALK gene rearrangements. The product is an oral inhibitor of the mutations...